GE builds diagnostics business with $587M Clarient buyout

GE on Friday announced plans to buy Clarient--a molecular diagnostics company with a strong focus on cancer markers--for $587 million. GE Healthcare is planning to build itself into a billion-dollar business marketing diagnostic solutions for healthcare providers. Story

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”